Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

NCT04092270 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04092270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04092270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 7, 2020
Completion date
June 8, 2027
Enrollment
55 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial high grade endometrioid adenocarcinoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube high grade serous adenocarcinoma, fallopian tube malignant mixed mesodermal (mullerian) tumor, fallopian tube mucinous adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, figo grade 1 endometrial endometrioid adenocarcinoma, figo grade 2 endometrial endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, ovarian seromucinous carcinoma, ovarian undifferentiated carcinoma, platinum-sensitive ovarian carcinoma, primary peritoneal carcinosarcoma, primary peritoneal high grade serous adenocarcinoma, primary peritoneal transitional cell carcinoma, primary peritoneal undifferentiated carcinoma, recurrent fallopian tube carcinoma, recurrent low grade fallopian tube serous adenocarcinoma, recurrent ovarian carcinoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian low grade serous adenocarcinoma, recurrent ovarian malignant mixed mesodermal (mullerian) tumor, recurrent ovarian mucinous adenocarcinoma, recurrent ovarian transitional cell carcinoma, recurrent primary peritoneal carcinoma, recurrent primary peritoneal low grade serous adenocarcinoma